Dalbavancin is a second generation, semi-synthetic lipoglycopeptide antibiotic that is active against Gram-positive bacteria. It was designed to improve upon the natural glycopeptides currently available (vancomycina and teicoplanin) and was launched in 2014. It is used to combat the bacteria causing acute bacterial skin and skin structure infections.
